Category - Developments

Developments

BiondVax, NIAID in Phase 2 trial of universal flu vaccine

BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) signed a clinical trial agreement for a Phase 2 clinical trial with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The study is designed to evaluate...

November 20, 2017

Developments

Oramed to conduct NASH study with oral insulin capsule

Oramed Pharmaceuticals (NASDAQ:ORMP) received approval from Israel’s Ministry of Health to initiate an exploratory clinical study of its oral insulin capsule, ORMD-0801, in patients with nonalcoholic...

November 14, 2017

Developments

Theralase researcher discovers potent anti-cancer drugs

Theralase Technologies (OTCQX:TLTFF; TSXV:TLT) recently identified a new platform of super potent anti-cancer drugs, or PDCs, discovered by Dr. Sherri McFarland, Professor, Department of Chemistry and Biochemistry...

November 14, 2017

Developments

Cellect CEO to be keynote speaker at regenerative medicine conference

Cellect Biotechnology (NASDAQ, TASE:APOP) CEO, Dr. Shai Yarkoni, was selected to provide the keynote presentation at the 11th World Congress of Regenerative Medicine and Stem Cell Technologies in Singapore. The event is...

November 10, 2017

Developments

IntelGenx seeks Health Canada approval for montelukast VersaFilm trial

IntelGenx (OTCQX:IGXT; TSXV:IGX) submitted a clinical trial application to Health Canada for approval to initiate a Phase 2a proof-of-concept study with montelukast in mild-to-moderate Alzheimer’s disease (AD)...

November 10, 2017

Developments

Profound Medical expands use of TULSA-PRO to BPH

Profound Medical (OTCQX:PRFMF; TSXV:PRN) announced that benign prostatic hyperplasia (BPH) treatments utilizing TULSA-PRO are now being successfully conducted in Germany. BPH is a non-cancerous enlargement of the...

November 6, 2017

Developments

Flex Pharma reports positive Phase 2 ALS cramping data

Flex Pharma (NASDAQ:FLKS) announced positive topline data for FLX-787 from its placebo-controlled, crossover Australian trial in amyotrophic lateral sclerosis (ALS) patients with frequent muscle cramps. The study was...

November 6, 2017

Developments

IntelGenx, RedHill Biopharma resubmit RIZAPORT NDA to FDA

IntelGenx (OTCQX:IGXT; TSXV:IGX) and RedHill Biopharma (NASDAQ, TASE:RDHL) resubmitted the 505(b)(2) NDA to the FDA for RIZAPORT 10 mg, an oral thin-film formulation of rizatriptan for the treatment of acute migraines...

November 1, 2017

Developments

Oramed gets EU notice of broad patent claims for oral proteins

The European Patent Office has issued to Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) a notice of intent to grant a patent for broader claims for its invention titled, “Methods and Compositions for Oral Administration of...

October 31, 2017

Developments

Mateon updates Phase 1b AML data

Mateon Therapeutics (OTCQX:MATN) announced updated data from the fifth dose cohort of OX1222, a Phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid...

October 30, 2017

Category - Developments

BiondVax, NIAID in Phase 2 trial of universal flu vaccine

Oramed to conduct NASH study with oral insulin capsule

Theralase researcher discovers potent anti-cancer drugs

Cellect CEO to be keynote speaker at regenerative medicine conference

IntelGenx seeks Health Canada approval for montelukast VersaFilm trial

Profound Medical expands use of TULSA-PRO to BPH

Flex Pharma reports positive Phase 2 ALS cramping data

IntelGenx, RedHill Biopharma resubmit RIZAPORT NDA to FDA

Oramed gets EU notice of broad patent claims for oral proteins

Mateon updates Phase 1b AML data

General

More